TY - JOUR AU - Seeff, L. B. AU - Buskell-Bales, Z. AU - Wright, E. C. PY - 1992 DA - 1992// TI - Long-term mortality after transfusion-associated non-a, non-B hepatitis. The National Heart, Lung, and Blood Institute study group JO - N Engl J Med VL - 327 UR - https://doi.org/10.1056/NEJM199212313272703 DO - 10.1056/NEJM199212313272703 ID - Seeff1992 ER - TY - JOUR AU - Mohd Hanafiah, K. AU - Groeger, J. AU - Flaxman, A. D. PY - 2013 DA - 2013// TI - Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence JO - Hepatology VL - 57 UR - https://doi.org/10.1002/hep.26141 DO - 10.1002/hep.26141 ID - Mohd Hanafiah2013 ER - TY - JOUR AU - Kumada, H. AU - Suzuki, Y. AU - Ikeda, K. PY - 2014 DA - 2014// TI - Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection JO - Hepatology VL - 59 UR - https://doi.org/10.1002/hep.27113 DO - 10.1002/hep.27113 ID - Kumada2014 ER - TY - JOUR AU - Mizokami, M. AU - Yokosuka, O. AU - Takehara, T. PY - 2015 DA - 2015// TI - Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial JO - Lancet Infect Dis VL - 15 UR - https://doi.org/10.1016/S1473-3099(15)70099-X DO - 10.1016/S1473-3099(15)70099-X ID - Mizokami2015 ER - TY - JOUR AU - Afdhal, N. AU - Zeuzem, S. AU - Kwo, P. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1402454 DO - 10.1056/NEJMoa1402454 ID - Afdhal2014 ER - TY - JOUR AU - Afdhal, N. AU - Reddy, K. R. AU - Nelson, D. R. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1316366 DO - 10.1056/NEJMoa1316366 ID - Afdhal2014 ER - TY - JOUR AU - Kowdley, K. V. AU - Gordon, S. C. AU - Reddy, K. R. PY - 2014 DA - 2014// TI - Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1402355 DO - 10.1056/NEJMoa1402355 ID - Kowdley2014 ER - TY - JOUR AU - Zeuzem, S. AU - Dusheiko, G. M. AU - Salupere, R. PY - 2014 DA - 2014// TI - Sofosbuvir and ribavirin in HCV genotypes 2 and 3 JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1316145 DO - 10.1056/NEJMoa1316145 ID - Zeuzem2014 ER - TY - JOUR AU - Levin, J. M. AU - Dabirshahsahebi, S. AU - Bauer, M. PY - 2016 DA - 2016// TI - Retrospective analysis of hepatitis C infected patients treated through an integrated care model JO - World J Gastroenterol VL - 22 UR - https://doi.org/10.3748/wjg.v22.i38.8558 DO - 10.3748/wjg.v22.i38.8558 ID - Levin2016 ER - TY - JOUR AU - Sebhatu, P. AU - Martin, M. T. PY - 2016 DA - 2016// TI - Genotype 1 hepatitis C virus and the pharmacist’s role in treatment JO - Am J Health Syst Pharm VL - 73 UR - https://doi.org/10.2146/ajhp150704 DO - 10.2146/ajhp150704 ID - Sebhatu2016 ER - TY - JOUR AU - Kimura, M. AU - Go, M. AU - Iwai, M. AU - Usami, E. AU - Teramachi, H. AU - Yoshimura, T. PY - 2017 DA - 2017// TI - Usefulness of a pharmacist outpatient service for S-1 adjuvant chemotherapy in patients with gastric cancer JO - Mol Clin Oncol VL - 7 UR - https://doi.org/10.3892/mco.2017.1337 DO - 10.3892/mco.2017.1337 ID - Kimura2017 ER - TY - JOUR AU - Zaepfel, M. AU - Cristofaro, L. AU - Trawinski, A. PY - 2017 DA - 2017// TI - Evaluation of a hepatitis C patient management program at a university specialty pharmacy JO - Ann Pharmacother VL - 51 UR - https://doi.org/10.1177/1060028016683495 DO - 10.1177/1060028016683495 ID - Zaepfel2017 ER - TY - STD TI - Tamori A, Hai H, Uchida-Kobayashi S, et al. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. Ann Hepatol. 2017;16:734–41. ID - ref13 ER - TY - STD TI - Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8:1935–7. ID - ref14 ER - TY - JOUR AU - Younossi, Z. M. AU - Stepanova, M. AU - Henry, L. PY - 2016 DA - 2016// TI - Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens JO - Medicine VL - 95 UR - https://doi.org/10.1097/MD.0000000000004151 DO - 10.1097/MD.0000000000004151 ID - Younossi2016 ER - TY - JOUR AU - Butt, A. A. AU - Yan, P. AU - Shaikh, O. S. PY - 2016 DA - 2016// TI - Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES JO - Liver Int VL - 36 UR - https://doi.org/10.1111/liv.13103 DO - 10.1111/liv.13103 ID - Butt2016 ER - TY - JOUR AU - Gauthier, T. P. AU - Moreira, E. AU - Chan, C. PY - 2016 DA - 2016// TI - Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution JO - J Am Pharm Assoc VL - 56 UR - https://doi.org/10.1016/j.japh.2016.06.013 DO - 10.1016/j.japh.2016.06.013 ID - Gauthier2016 ER - TY - JOUR AU - Yang, S. AU - Britt, R. B. AU - Hashem, M. G. PY - 2017 DA - 2017// TI - Outcomes of pharmacy-led hepatitis C direct-acting antiviral utilization management at a veterans affairs medical center JO - J Manag Care Spec Pharm VL - 23 UR - https://doi.org/10.18553/jmcp.2017.23.3.364 DO - 10.18553/jmcp.2017.23.3.364 ID - Yang2017 ER - TY - JOUR AU - Grebely, J. AU - Mauss, S. AU - Brown, A. PY - 2016 DA - 2016// TI - Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials JO - Clin Infect Dis VL - 63 UR - https://doi.org/10.1093/cid/ciw580 DO - 10.1093/cid/ciw580 ID - Grebely2016 ER - TY - JOUR AU - Grebely, J. AU - Dore, G. J. AU - Zeuzem, S. PY - 2016 DA - 2016// TI - Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials JO - Clin Infect Dis VL - 63 UR - https://doi.org/10.1093/cid/ciw579 DO - 10.1093/cid/ciw579 ID - Grebely2016 ER - TY - JOUR AU - Petersen, T. AU - Townsend, K. AU - Gordon, L. A. PY - 2016 DA - 2016// TI - High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study JO - Hepatol Int VL - 10 UR - https://doi.org/10.1007/s12072-015-9680-7 DO - 10.1007/s12072-015-9680-7 ID - Petersen2016 ER - TY - JOUR AU - Oza, N. AU - Isoda, H. AU - Ono, T. PY - 2017 DA - 2017// TI - Current activities and future directions of comprehensive hepatitis control measures in Japan: the supportive role of the hepatitis information center in building a solid foundation JO - Hepatol Res VL - 47 UR - https://doi.org/10.1111/hepr.12897 DO - 10.1111/hepr.12897 ID - Oza2017 ER -